01—Abstract
Summary
Summary of the 8-K filed June 24, 2024. Cited figures are marked; the original filing is the authoritative source.
BridgeBio Pharma, Inc. reported the results of its Annual Meeting of Stockholders, held June 21, 2024, in this Current Report.
Of the 187,129,260 shares of common stock entitled to vote, 160,899,203 were present or represented by valid proxy. Stockholders elected all five Class II director nominees (Eric Aguiar, M.D., Jennifer E. Cook, Andrea J.
Ellis, Fred Hassan and Ali J. Satvat) to terms ending at the 2027 Annual Meeting. Ali J.
Satvat received the lowest support, with 106,237,448 votes for and 37,395,306 withheld, compared with 137,076,192 to 139,229,888 votes for the other four nominees. Stockholders also approved, on a non-binding advisory basis, the compensation of the named executive officers, with 134,309,832 votes for, 9,254,636 against and 68,286 abstentions. They ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, with 160,661,642 votes for, 196,629 against and 40,932 abstentions.
Stockholders approved an amendment and restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan, which, among other things, increases the number of shares reserved for issuance by 6,500,000 shares. The vote was 118,318,376 for, 25,003,526 against and 310,852 abstentions, with 17,266,449 broker non-votes. The amended plan is filed as Exhibit 10.1.
02—Key points
Key Highlights
- Annual Meeting held June 21, 2024, with 160,899,203 of 187,129,260 eligible shares present or represented by proxy
- All five Class II director nominees elected to serve until the 2027 Annual Meeting
- Ali J. Satvat drew the most withheld votes among nominees, at 37,395,306, versus 4,402,866 to 6,556,562 for the other nominees
- Non-binding say-on-pay proposal approved, with 134,309,832 votes for and 9,254,636 against
- Deloitte & Touche LLP ratified as independent registered public accounting firm for fiscal 2024 with 160,661,642 votes for
- 2021 Stock Option and Incentive Plan amended and restated, increasing the reserved share pool by 6,500,000 shares, with 118,318,376 votes for and 25,003,526 against
- The amended 2021 Plan is filed as Exhibit 10.1
03—Questions
Frequently Asked Questions
Who was elected to the Board of Directors at the June 21, 2024 Annual Meeting?
Stockholders elected Eric Aguiar, M.D., Jennifer E. Cook, Andrea J. Ellis, Fred Hassan and Ali J. Satvat as Class II directors. Each will hold office until the 2027 Annual Meeting or until a successor is duly elected and qualified.
Did any director nominee receive notably weaker support?
Yes. Ali J. Satvat received 106,237,448 votes for and 37,395,306 votes withheld. The other four nominees received between 137,076,192 and 139,229,888 votes for, with between 4,402,866 and 6,556,562 votes withheld.
What did stockholders decide on executive compensation?
On a non-binding, advisory basis, stockholders approved the compensation of the named executive officers. The filing reports 134,309,832 votes for, 9,254,636 against and 68,286 abstentions, with 17,266,449 broker non-votes.
What is changing under the amended 2021 Stock Option and Incentive Plan?
Stockholders approved an amendment and restatement that, among other things, increases the number of shares of common stock reserved for issuance under the plan by 6,500,000 shares. The approved plan is filed as Exhibit 10.1 to this report.
Who is the company's independent auditor for fiscal 2024?
Stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The vote was 160,661,642 for, 196,629 against and 40,932 abstentions, with zero broker non-votes.
04—Continue